ZERIT XR — FDA application NDA021453
Listed sponsor: BRISTOL MYERS SQUIBB · BMY company profile · exact_unique
Sponsor as listed in Drugs@FDA at retrieval (2026-08-07); FDA sponsor listings can lag ownership transfers.
FDA application facts
| Product | FDA-listed trade name | Active ingredient | Dosage form | Route | Strength | Marketing status | TE code | RLD |
|---|---|---|---|---|---|---|---|---|
| 001 | ZERIT XR | STAVUDINE | CAPSULE, EXTENDED RELEASE | ORAL | 37.5MG | Discontinued | not listed | No |
| 002 | ZERIT XR | STAVUDINE | CAPSULE, EXTENDED RELEASE | ORAL | 50MG | Discontinued | not listed | No |
| 003 | ZERIT XR | STAVUDINE | CAPSULE, EXTENDED RELEASE | ORAL | 75MG | Discontinued | not listed | No |
| 004 | ZERIT XR | STAVUDINE | CAPSULE, EXTENDED RELEASE | ORAL | 100MG | Discontinued | not listed | No |
Product, form, strength, reference-drug and marketing-status fields: Drugs@FDA data files; TE and RLD fields: Orange Book data files. Retrieved 2026-08-07.
Orange Book patent and exclusivity listings
No Orange Book patent or exclusivity listings joined to this application.
Compound cross-links
- STAVUDINE · UNII not resolved · no lmmol compound match
Ingredient–compound links use FDA openFDA/GSRS identifiers and an exact lmmol InChIKey join. Ingredient names cannot create a link.
Related pages
Sponsor company · FDA-approved application index
Peer clusters: Large-cap biopharma
Sources: Drugs@FDA · Orange Book · openFDA application record. FDA data retrieved 2026-08-07.
Regulatory listing data as published by FDA; not medical or investment advice.